What is CRVO's current stock price?

CRVO (CervoMed Inc.) is currently trading at $3.01 with a market cap of $27.9M.

What sector is CervoMed Inc. in?

CervoMed Inc. (CRVO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CRVO a good stock to buy?

Analysts have a Buy consensus on CRVO with a price target of $9.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CRVO CervoMed Inc.

Healthcare

$3.01+0.00%OpenMarket Cap: $27.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.67

P/S

87.83

EV/EBITDA

-0.66

DCF Value

$0.80

FCF Yield

-97.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-9642.1%

Net Margin

-9311.6%

ROE

-136.1%

ROA

-198.7%

ROIC

-242.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-8.0M	$—
Q4 null	$0.00	$-8.1M	$—
FY null	$0.00	$-27.0M	$—
Q3 null	$322.6K	$-7.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$9.00 - $9.00

0 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-23

D. Boral CapitalBuy

2026-04-22

D. Boral CapitalBuy

2026-03-19

Roth CapitalBuy

2026-03-18

Chardan CapitalBuy

2026-03-18

Trading Activity

Insider Trades

View All

Winton Matthewofficer: Chief Commercial and Business

SellFri Feb 13

Gregoire Sylviedirector, 10 percent owner:

SellFri Feb 13

ELDER WILLIAM ROBERTofficer: CFO, GC & Secretary

SellFri Feb 13

De Rosch Markofficer: EVP, RA and GA and PgM

SellFri Feb 13

Blackburn Kellyofficer: EVP, Clinical Development

SellFri Feb 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-4.47

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Peers